Alnylam Pharmaceuticals

ALNYApproved

Cambridge, United StatesFounded 2002alnylam.com

Founded in 2002, Alnylam Pharmaceuticals is a leading biopharmaceutical company that pioneered the RNAi therapeutics revolution. The company leverages RNA interference technology to selectively silence genes that cause or contribute to disease, offering a fundamentally different approach to treating genetic disorders. With multiple approved therapies and a strong pipeline focused on rare diseases, Alnylam has established itself as the definitive leader in RNAi therapeutics with global reach and operations.

Market Cap

$41.4B

Founded

2002

Employees

1,000-2,000

Focus

RNA & Gene Therapy

ALNY · Stock Price

USD 312.17+148.36 (+90.57%)

Historical price data

AI Company Overview

Technology Platform

RNA interference (RNAi) therapeutics platform that selectively silences disease-causing genes using advanced delivery systems including lipid nanoparticles and GalNAc conjugation technology for targeted tissue delivery.

Pipeline Snapshot

73 drugs in pipeline, 14 in Phase 3

Drug	Indication	Stage
Patisiran	Amyloidosis, Familial	Phase 3
patisiran (ALN-TTR02) + Sterile Normal Saline (0.9% NaCl)	TTR-mediated Amyloidosis	Phase 3
Placebo + Patisiran	Transthyretin Amyloidosis (ATTR) With Cardiomyopathy	Phase 3
Givosiran + Placebo	Acute Hepatic Porphyria	Phase 3
Nucresiran + Vutrisiran	Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy	Phase 3

Funding History

Total raised: $179M

Series C$68MSkyline VenturesMar 15, 2005

IPO$49MUndisclosedJun 30, 2004

Series B$38MPolaris PartnersJun 15, 2003

Series A$24MMPM CapitalJan 15, 2002

FDA Approved Drugs

AMVUTTRANDAJun 13, 2022

OXLUMONDANov 23, 2020

GIVLAARINDANov 20, 2019

Opportunities

Significant expansion opportunities exist in applying RNAi technology to prevalent diseases beyond rare disorders, developing next-generation delivery platforms for enhanced tissue targeting, and leveraging the scalable platform to rapidly advance multiple pipeline programs toward commercialization.

Risk Factors

Key risks include potential clinical trial failures in late-stage programs, increasing competition from large pharmaceutical companies entering the RNAi space, manufacturing complexities that could impact supply chain reliability, and regulatory challenges in global markets.

Competitive Landscape

Alnylam maintains clear market leadership as the pioneer in RNAi therapeutics with the most advanced platform and largest commercial portfolio. Main competitors include emerging RNAi companies and large pharma developing genetic medicines, but Alnylam's first-mover advantage, extensive IP portfolio, and proven commercial execution create significant competitive moats.

Publications

Patents

Pipeline

FDA Approvals